IL-6 R alpha

IL-6 R alpha

IL-6 R alpha Informations sur la molécule

Molecule Name
Interleukin-6 receptor alpha subunit
Alias de la molécule
IL6R,CD126,IL-6R-1,IL-6RA,IL6RA,IL-6R-alpha,IL6RQ,gp80
Drug Development Progress
Nombre de médicaments cliniques9
Nombre de médicaments commercialisés8
Phase de R&D la plus avancéeApproved
Alias de la cible
IL6RA,IL6RQ,IL6Q,Interleukin-6 Receptor alpha Subunit,sIL6R,gp80,IL-6R subunit alpha,Membrane glycoprotein 80,IL6R,Interleukin 6 Receptor,IL-6 Receptor Subunit Alpha,CD126 Antigen,IL-6R 1,IL-6RA,Interleukin-6 Receptor Subunit Alpha,IL-6R-Alpha,IL-6R-1,CD126
Contexte de la molécule
Interleukin 6 receptor (IL6R) is also known as CD126 (Cluster of Differentiation 126) , is a potent pleiotropic cytokine that regulates cell growth and differentiation of various tissues, and is known particularly for its role in the immune response and acute phase reactions. IL6R is a protein complex consisting of a IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. IL6R also denotes the human gene encoding this subunit. Alternatively spliced transcript variants encoding distinct isoforms have been reported. IL6R subunit also shared by many other cytokines. The soluble form of IL6R arises from proteolytic cleavage of membrane-bound IL6Rα, and acts agonistically by making the IL6 ligand accessible to the signal transducer gp130. Dysregulated production of IL6 and IL6R are implicated in the pathogenesis of several inflammatory diseases and malignancies such as multiple myeloma, rheumatoid arthritis, or osteoporosis, and it has been reported that a humanized anti-IL6R monoclonal antibody is a promising agent applicable to the therapeutic approach for IL6 driven diseases. Interleukin-6 receptor has been shown to interact with Interleukin 6 and Ciliary neurotrophic factor.

IL-6 R alpha Liste de produits

Species
  • Human(4)
  • Mouse(2)
  • Rhesus macaque(1)
Tag
  • Fc Tag(2)
  • His Tag(2)
  • His Tag & Avi Tag(2)
  • Fc Tag & Avi Tag(1)
Host
  • HEK293(7)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(3)
Grade
  • RUO(7)
Low Endotoxin
  • Yes(1)
  • No(6)
You Have Viewed 1-7 Of 7 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Recombinant humanized anti-IL-6R antibody (Hisun Pharma)HS-628Phase 3 ClinicalZhejiang Hisun Pharmaceutical Co Ltd
Arthritis; Arthritis, Rheumatoid
Details
VDJ-001Phase 3 ClinicalBeijing Vdjbio Co Ltd
Arthritis, Rheumatoid; Cardiovascular Diseases; Castleman Disease; Graves Ophthalmopathy; Multicentric Castleman's Disease (MCD); Renal Insufficiency, Chronic
Details
Tocilizumab Biosimilar (Curateq Biologics)BP08; BP-08Phase 3 ClinicalCuraTeQ Biologics Pvt Ltd
Arthritis, Rheumatoid
Details
Tocilizumab biosimilar (GENERIUM Pharmaceuticals)GNR-087Phase 3 ClinicalGenerium Pharmaceuticals
Arthritis, Rheumatoid
Details
Tocilizumab biosimilar (AryoGen Pharmed)Phase 3 ClinicalAryogen Biopharma
Arthritis, Rheumatoid
Details
Tocilizumab biosimilar(Hetero Biopharma)Phase 3 ClinicalHetero Biopharma Ltd
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)
Details
LevilimabBCD-089Phase 3 ClinicalBIOCAD JSC
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)
Details
Atexakin alfaSON-080; r-IL-6Phase 2 ClinicalWeizmann Institute Of Science
Diabetic Neuropathies; Peripheral Nervous System Diseases
Details
OlamkiceptFE-999301; CR-5/18; TJ-301; FE-301Phase 1 ClinicalConaris Research Institute
Colitis, Ulcerative; Gastrointestinal Diseases
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
TocilizumabMRA-SC; R-1569; rhPM-1; RO-48775533; MRA; RG-1569; HPM-1ApprovedChugai Pharmaceutical Co LtdActemra, Acterma, ACTPen, RoActemra, 雅美罗JapanArthritis, RheumatoidChugai Pharmaceutical Co Ltd2005-04-11
Acute Chest Syndrome; Amyotrophic Lateral Sclerosis; Anemia, Sickle Cell; Arthritis, Juvenile; Arthritis, Rheumatoid; Ascites; Behcet Syndrome; Breast Neoplasms; Carcinoma, Hepatocellular; Chondrocalcinosis; Coronary Artery Disease; Coronary Disease; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Craniopharyngioma; Cytokine Release Syndrome; Depressive Disorder, Major; Dermatomyositis; Diabetes Mellitus; Diabetes Mellitus, Type 1; Fever; Giant Cell Arteritis; Graft vs Host Disease; Graves Ophthalmopathy; Hematologic Neoplasms; HIV Infections; Inflammation; Ischemic Stroke; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Lymphoma; Motor Neuron Disease; Myocardial Infarction; Neoplasms; Non-radiographic axial spondyloarthritis; Non-ST Elevated Myocardial Infarction; Osteoarthritis; Pancreatitis, Chronic; Panuveitis; Pleural Effusion, Malignant; Pneumonia; Polyarticular Juvenile Idiopathic Arthritis; Polymyalgia Rheumatica; Polymyositis; Pulmonary Arterial Hypertension; Pulmonary Disease,
Details
Tocilizumab biosimilar (Bio-Thera Solutions)BAT-1806; BIIB-800ApprovedBio-Thera Solutions Ltd施瑞立, TOFIDENCEMainland ChinaArthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release SyndromeBio-Thera Solutions Ltd2023-01-16
Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis
Details
SarilumabSAR-153191; REGN-88ApprovedRegeneron Pharmaceuticals Inc, SanofiKevzaraUnited StatesArthritis, RheumatoidSanofi-Synthelabo2017-05-22
Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Polyarticular Juvenile Idiopathic Arthritis; Polymyalgia Rheumatica; Sarcoidosis; Severe Acute Respiratory Syndrome; Spondylitis, Ankylosing; Uveitis
Details
Tocilizumab biosimilar (Livzon Group)LZM-008ApprovedLivzon Pharmaceutical Group Inc安维泰Mainland ChinaArthritis, RheumatoidLivzon Mabpharm Inc2023-01-18
Arthritis, Rheumatoid
Details
Tocilizumab biosimilar (Fresenius kabi)MSB-11456; AT-220 (Arecor Therapeutics)ApprovedMerck SeronoTyenneEUCoronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell ArteritisFresenius Kabi Deutschland Gmbh2023-09-15
Arthritis, Rheumatoid; Brain Ischemia; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Subarachnoid Hemorrhage
Details
Tocilizumab biosimilar (BioRay Pharm)ApprovedHisun Biopharmaceutical Co LtdMainland ChinaArthritis, RheumatoidHisun Biopharmaceutical Co Ltd2024-06-25
Arthritis, Rheumatoid
Details
Tocilizumab biosimilar (Celltrion)CT-P47; CT-P-47ApprovedCelltrion IncAvtozmaUnited StatesGiant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile; Arthritis, RheumatoidCelltrion Inc2025-01-24
Arthritis, Juvenile; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis
Details
Tocilizumab biosimilar (Maibo Taike)CMAB-806; CMAB806ApprovedJinyu Bowo Runze Biotechnology Co Ltd, Taizhou Maibo Taike Biotechnology Co LtdMainland ChinaArthritis, RheumatoidJinyu Bowo Runze Biotechnology Co Ltd2024-10-16
Arthritis; Arthritis, Rheumatoid
Details
Customer Reviews